Predictive value of HBsAg quantification in pegylated interferon therapy for chronic hepatitis B / 临床肝胆病杂志
Journal of Clinical Hepatology
;
(12): 977-980, 2016.
Article
in Chinese
| WPRIM
| ID: wpr-778642
ABSTRACT
Antiviral therapy is the most important thing in the treatment of chronic hepatitis B (CHB). Pegylated interferon (PEG-IFN) has both antiviral and immunomodulatory effects, and after drug withdrawal, 30%-40% of patients can achieve HBeAg seroconversion and sustained virologic response. Many studies have shown that HBsAg quantification can be used as an index to predict the anti-HBV effect of PEG-IFN and sustained immune control after drug withdrawal. This article reviews the relationship between HBsAg levels before, during, and after PEG-IFN therapy and antiviral effect to clarify the significance of HBsAg quantification in the PEG-IFN treatment of CHB and to guide the regimen of antiviral therapy.
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Prognostic study
Language:
Chinese
Journal:
Journal of Clinical Hepatology
Year:
2016
Type:
Article
Similar
MEDLINE
...
LILACS
LIS